Effectiveness of palivizumab prophylaxis in infants and children in Florida

Item

http://www.wikidata.org/entity/Q57830092

description

scientific article published on 15 September 2011

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2011

@uk

name

Effectiveness of palivizumab prophylaxis in infants and children in Florida

@en

Effectiveness of palivizumab prophylaxis in infants and children in Florida

@nl

type

Item

label

Effectiveness of palivizumab prophylaxis in infants and children in Florida

@en

Effectiveness of palivizumab prophylaxis in infants and children in Florida

@nl

prefLabel

Effectiveness of palivizumab prophylaxis in infants and children in Florida

@en

Effectiveness of palivizumab prophylaxis in infants and children in Florida

@nl

P1476

Effectiveness of palivizumab prophylaxis in infants and children in Florida

@en

P2093

Arwa Saidi

http://www.w3.org/2001/XMLSchema#string

P2860

Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections

Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group.

Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review.

Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants.

Risk of bacterial infection in previously healthy respiratory syncytial virus-infected young children admitted to the intensive care unit.

Multiple viral respiratory pathogens in children with bronchiolitis

Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group.

Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.

Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.

Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida.

P304

53-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PDS.2246

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Almut G. Winterstein

Christian Hampp

P577

2011-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21919115

http://www.w3.org/2001/XMLSchema#string